OPIOID INDUCED CONSTIPATION DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-48952 | Life Sciences
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Opioid Induced Constipation Drugs Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL OPIOID INDUCED CONSTIPATION DRUGS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL OPIOID INDUCED CONSTIPATION DRUGS MARKET
7.1 GLOBAL OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Ironwood Pharmaceuticals Inc
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Daiichi Sankyo Co Ltd
16.3 Pfizer
16.4 Progenics Pharmaceuticals Inc
16.5 Shionogi & Co Ltd
16.6 Allergan Plc
16.7 Nektar Therapeutics
16.8 Purdue Pharma
16.9 SLA Pharma AG
16.10 Mundipharma International Limited
16.11 Ono Pharmaceutical Co Ltd
16.12 Takeda Pharmaceutical Company Limited
16.13 Theravance Biopharma Inc
16.14 Valeant Pharmaceuticals International
16.15 Cosmo Pharmaceuticals SA
16.16 Daewoong Pharmaceutical
16.17 CB Fleet Company
16.18 Sucampo Pharmaceuticals
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Market by TypeLubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Others
Market by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Companies
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
SLA Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Valeant Pharmaceuticals International
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
CB Fleet Company
Sucampo Pharmaceuticals
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.